Post-Marketing Study to Assess the Safety and Effectiveness of Oral Atogepant in Korean Adult Participants for the Prevention of Chronic or Episodic Migraine
Recruiting
Observational Study
Chronic Migraine
Episodic Migraine
Migraine
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 19 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 3,000 (estimated)
- Sponsor
- AbbVie · Industry
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound. The study will assess the safety and effectiveness of atogepant for the preventive treatment of migraine in Korean adult patients with chronic migraine or episodic migraine under routine clinical practice.
Atogepant is an approved drug for preve…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Participants with migraine suitable for the treatment with atogepant according to the latest approved local label.
* Participants prescribed atogepant in accordance with the approved local label.
Exclusion Criteria:
* Participants with any contraindication to atogepant as li…
Contacts